Montelukast: More than a cysteinyl leukotriene receptor antagonist?

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 2403-2413

  Tintinger, Gregory R ^a   Feldman, Charles ^b   Theron, Annette J ^c   Anderson, Ronald ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

5 lipoxygenase; Chronic obstructive pulmonary disease; Cyclic AMP; Cyclic nucleotide phospodiesterase; Cysteinyl leukotrienes; Cystic fibrosis; Histone acetyltransferase; Sepsis; Viral bronchiolitis

Indexed keywords

7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CR 3465; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; HISTONE ACETYLTRANSFERASE; IBUDILAST; MN 166; MONTELUKAST; PHOSPHODIESTERASE; PRANLUKAST; PURINERGIC P2Y RECEPTOR; TOMELUKAST; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; BRONCHOSPASM; CELL ADHESION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC URTICARIA; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG MECHANISM; ENZYME INHIBITION; EOSINOPHIL; FUNGAL SINUSITIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTERSTITIAL CYSTITIS; IRRITABLE COLON; LIVER ISCHEMIA; LUNG FIBROSIS; NOSE POLYP; OTITIS MEDIA; PANCREATITIS; PARANASAL SINUS DISEASE; REPERFUSION INJURY; SEPSIS; SHORT SURVEY; SYSTEMIC MASTOCYTOSIS; VAGINA CANDIDIASIS; VIRAL BRONCHIOLITIS;

ACETATES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLINES; RECEPTORS, LEUKOTRIENE;

EID: 78650277518     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.229     Document Type: Short Survey

References (80)

1. Peters-Golden, M. and Henderson, W.R. (2007) Leukotrienes. N. Engl. J. Med. 357, 1841-1854.
2. Gualano, R.C., Vlahos, R., and Anderson, G.P. (2006) What is the contribution of respiratory viruses and lung proteases to airway remodelling in asthma and chronic obstructive pulmonary disease? Pulm. Pharmacol. Ther. 19, 18-23.
3. Lagente, V. and Boichot, E. (2009) Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J. Mol. Cardiol. 48(3), 440-444.
4. 4 sensitize human neutrophils for hyperreactivity to chemoattractants. Inflamm. Res. 57, 1-6.
5. Bateman, E.D., Hurd, S.S., Barnes, P.J., Bousquet, J., Drazen, J.M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S.E., Pizzichini, E., Sullivan, S.D., Wenzel, S.E., and Zar, H.J. (2008) Global strategy for asthma management and prevention: GINA executive summery. Eur. Respir. J. 31,143-178.
6. Ramires, R., Caiaffa, M.E., Tursi, A., Haeggström, J.Z., and Macchia, L. (2004) Novel inhibitory effects on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem. Biophys. Res. Commun. 324, 815-821.
7. Tahan, F., Jazrawi, T., Rovati, G.E., and Adcock, I.M. (2008) Montelukast inhibits tumour necrosis factor-α-mediated interleukin-8 expression through inhibition of nuclear factor-κB p65-associated histone acetyltransferase activity. Clin. Exp. Allergy 38, 805-811.
8. Anderson, R., Theron, A.J., Gravett, C.M., Steel, H.C., Tintinger, G.R., and Feldman, C. (2009) Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br. J. Pharmacol. 156, 105-115.
9. 1R antagonism. J. Leukoc. Biol. 83. 1522-1529.
10. Serezani, C.H., Ballinger, M.N., Aronoff, D.M., and Peters-Golden, M. (2008) Cyclic AMP. Master regulator of innate immune cell function. Am. J. Respir. Cell Mol. Biol. 39, 127-132.
11. Ali, H., Sozzani, S., Fisher, I., Barr, A.J., Richardson, R.M., Haribabu, B., and Snyderman, R. (1998) Differential regulation of formyl peptide and platelet-activating factor receptors: role of phospholipase Cβ3 phosphorylation by protein kinase A. J. Biol. Chem. 273, 11012-11016.
12. 2+ influx in airway smooth muscle. Am. J. Physiol. Lung. Cell. Mol. Physiol. 290, L278-L283.
13. Woszczek, G., Chen, L.-Y., Alsaaty, S., Nagineni, S., and Shelhamer, J.H. (2010) Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists. J. Immunol. 184, 2219-2225.
14. Tintinger, G.R., Steel, H.C., Theron, A.J., and Anderson, R. (2008) Pharmacological control of neutrophil-mediated inflammation: strategies targeting calcium handling by activated polymorphonuclear leukocytes. Drug Des. Dev. Ther. 2, 95-104.
15. 2+ signaling requirements. Biochem. J. 337, 153-169.
16. Anderson, R. and Goolam Mahomed, A. (1997) Calcium efflux and influx in f-met-leu-phe (fMLP)-activated human neutrophils are chronologically distinct events. Clin. Exp. Immunol. 110, 132-138.
17. Torphy, T.J. (1998) Phosphodiesterase enzymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157, 351-370.
18. Tintinger, G.R., Theron, A.J., Anderson, R., and Ker, J.A. (2001) The anti-inflammatory interactions of epinephrine with human neutrophils in vitro are achieved by cyclic AMP-mediated accelerated resequestration of cytosolic calcium. Biochem. Pharmacol. 61, 1319-1328.
19. Moore, A.R. and Willoughby, D.A. (1995) The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 101, 387-389.
20. Cheng, H., Leff, J.A., Amin, R., Gertz, B.J., De Smet, M., Noonan, N., Rogers, J.D., Malbecq, W., Meisner, D., and Somers, G. (1996). Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm. Res. 13, 445-448.
21. Knorr, B., Holland, S., Schwartz, J., Rogers, J.D., and Reiss, T.F. (2001) Clinical pharmacology of montelukast. Clin. Exp. Allergy Rev. 1, 254-260.
22. Barnes, P.J. (2007) New molecular targets for the treatment of neutrophilic diseases. J. Allergy Clin. Immunol. 119, 1055-1062.
23. 4 in allergic diseases. Allergol. Int. 57, 291-298.
24. Steib, C.J., Bilzer, M., Op den Winkel, M., Pfeiler, S., Hartmann, A.C., Henneberg, M., Göke, B., and Gerbes, A.L. (2010) Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology 51, 2086-2096.
25. Ichiyama, T., Hasegawa, S., Umeda, M., Terai, K., Matsubara, T., and Furukawa, S. (2003) Pranlukast inhibits NF-κB activiation in human monocytes/macrophages and T cells. Clin. Exp. Allergy 33, 802-807.
26. Tomari, S., Matsuse, H., Machida, I., Kondo, Y., Kawano, T., Obase, Y., Fukushima, C., Shimoda, T., and Kohno, S. (2003) Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-specific tumour necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monoctyes from atopic asthmatics. Clin. Exp. Allergy 33, 795-801.
27. Ishinaga, H., Takeuchi, K., Kishioka, C., Suzuki, S., Basbaum, C., and Majima, Y. (2005) Pranlukast inhibits NF-κB activation and MUC2 gene expression in cultured human epithelial cells. Pharmacology 73, 89-96. (Pubitemid 40082319)
28. Fang, S.-H., Yuan, Y.-M., Peng, F., Li, C.-T., Zhang, L.-H., Lu, Y.-B., Zhang, W.-P., and Wei, E.-Q. (2009) Pranlukast attenuates ischemia-like injury in endothelial cells via inhibiting reactive oxygen species production and nuclear factor-κB activation. J. Cardiovasc. Pharmacol. 53, 77-85.
29. Maeba, S., Ichiyama, T., Ueno, Y., Makata, H., Matsubara, T., and Furukawa, S. (2005) Effect of montelukast on nuclear factor kappa B activation and proinflammatory molecules. Ann. Allergy Asthma Immunol. 94, 670-674.
30. Meliton, A.Y., Munoz, N.M., and Leff, A.R. (2007) Blockade of avidity and focal clustering of beta 2-integrin by cysteinyl leukotriene antagonism attenuates eosinophil adhesion. J. Allergy Clin. Immunol. 120, 1316-1323.
31. Profita, M., Sala, A., Bonanno, A., Siena, L., Ferraro, M., Di Giorgi, R., Montalbano, A.M., Albano, G.D., Gagliardo, R., and Gjomarkaj, M. (2008) Cysteinyl leukotriene-1 receptor activation in a human bronchial epithelial cell line leads to signal transducer and activator of transcription 1-mediated eosinophil adhesion. J. Pharmacol. Exp.Ther. 325, 1024-1030.
32. Langlois, A., Ferland, C., Trembly, G.M., and Laviolette, M. (2006) Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J. Allergy Clin. Immunol. 118, 113-119.
33. Idzko, M., Hammad, H., van Nimwegen, M., Kool, M., Willart, M.A., Muskens, F., Hoogsteden, H.C., Luttmann, W., Ferrari, D., Di Virgilio, F., et al. (2007) Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat. Med. 13, 913-919.
34. Chen, Y., Yao, Y., Sumi, Y., Li, A., To, U.K., Elkhal, A., Inoue, Y., Woehrle, T., Zhang, Q., Hauser, C., and Junger, W.G. (2010) Purinergic signaling: a fundamental mechanism in neutrophil activation. Sci. Signal. 3, ra45.
35. Grassi, F. (2010) Purinergic control of neutrophil activation. J. Mol. Cell. Biol. 2, 176-177.
36. Mamedova, L., Capra, V., Accomazzo, M.R., Gao, Z.-G., Ferrario, S., Fumagalli, M., Abbracchio, M.P., Rovati, E., and Jacobson, K.A. (2005) CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem. Pharmacol. 71, 115-125.
37. Gravett, C.M., Theron, A.J., Steel, H.C., Tintinger, G.R., Cockeran, R., Feldman, C., and Anderson, R. (2010) Interactive inhibitory effects of formoterol on activated human neutrophils. Eur. Respir. J. [Epub ahead of print]
38. Wang, P., Wu, P., Ohleth, K.M., Egan, R.W., and Billah, M.M. (1999) Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol. Pharmacol. 56, 170-174.
39. Anderson, R., Goolam Mahomed, A., Theron, A.J., Ramafi, G., and Feldman, C. (1998) Effects of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils. Br. J. Pharmacol. 124, 547-555.
40. Costantini, T.W., Deree, J., Peterson, C.Y., Putnam, J.G., Woon, T., Loomis, W.H., Bansal, V., and Coimbra, R. (2010) Pentoxifylline modulates p47phox activation and downregulates neutrophil oxidative burst through PKA-dependent and - independent mechanisms. Immunopharmacol. Immunotoxicol. 32, 82-91.
41. Flamand, N., Surette, M.E., Picard, S., Bourgoin, S., and Borgeat, P. (2002) Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol. Pharmacol. 62, 250-256.
42. Parry, G.C.N. and Mackman, N. (1997) Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-κB-mediated transcription. J. Immunol. 159, 5450-5456. (Pubitemid 127470072)
43. Fleisch, J.H., Rinkema, L.E., and Marshall, W.S. (1984) Pharmacologic receptors for the leukotrienes. Biochem. Pharmacol. 33, 3919-3922.
44. Hay, D.W.P., Muccitelli, R.M., Tucker, S.S., Vickery-Clark, L.M., Wilson, K.A., Gleason, J.G., Hall, R.F., Wasserman, M.A., and Torphy, T.J. (1987) Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J. Pharmacol. Exp. Ther. 243, 474-481.
45. 1 receptor antagonist with broad anti-inflammatory activity. Eur. J. Pharmacol. 504, 223-233.
46. Bernstein, P.R. (1998) Chemistry and structure - activity relationships of leukotriene receptor antagonists. Am. J. Respir. Crit. Care Med. 157, S220-S226.
47. http://www.rotta.com/en/service/rd/areTerap/bro.html
48. Ledeboer, A., Hutchinson, M.R., Watkins, L.R., and Johnson, K.W. (2007) Ibudilast (AV-411) a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin. Investig. Drugs 16, 935-950.
49. Barkhof, F., Hulst, H.E., Drulovic, J., Uitdehaag, B.M.J., Matsuda, K., and Landin, R. (2010) Ibudilast in relapsing-remitting multiple sclerosis. A neuroprotectant? Neurology 74, 1033-1040.
50. Capra, V., Ambrosio, M., Riccioni, G., and Rovati, G.E. (2006) Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr. Med. Chem. 13, 3213-3226.
51. Riccioni, G., Bucciarelli, T., Mancini, B., Di Ilio, C., and D'Orazio, N. (2007) Antileukotriene drugs: clinical application, effectiveness and safety. Curr. Med. Chem. 14, 1966-1977.
52. Drakatos, P., Lykouras, D., Sampsonas, F., Karkoulias, K., and Spiropoulos, K. (2009) Targeting leukotrienes for the treatment of COPD? Inflamm. Allergy Drug Targets 8(4), 297-306.
53. Dastidar, S.G., Rajagopal, D., and Ray, A. (2007) Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr. Opin. Investig. Drugs 8(5), 364-372.
54. Halpin, D.M.G. (2008) ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 3(4), 543-561.
55. Cosio, B.G., Tsaprouni, L., Ito, K., Jazrawi, E., Adcock, I.M., and Barnes, P.J. (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 200, 689-695.
56. Chung, K.F. (2006) Phosphodiesterase inhibitors in airways disease. Eur. J. Pharmacol. 533, 110-117.
57. Houslay, M.D., Schafer, P., and Zhang, K.Y.J. (2005) Phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 22, 1503-1519.
58. Lagente, V., Martin-Chouly, C., Boichot, E., Martins, M.A., and Silva, P.M.R. (2005) Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem. Inst. Oswaldo Cruz 100(Suppl. 1), 131-136.
59. Jesus Sanz, M., Cortijo, J., and Morcillo, E.J. (2005) PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol. Ther. 106, 269-297.
60. Boswell-Smith, V., Cazzola, M., and Page, C.P. (2006) Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin. Immunol. 117, 1237-1243.
61. Celik, P., Sakar, A., Havlucu, Y., Yuksel, H., Turkdogan, P., and Yorgancioglu, A. (2005) Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir. Med. 99, 444-450.
62. Rubinstein, I., Kumar, B., and Schriever, C. (2004) Long-term montelukast therapy in moderate to severe COPD - a preliminary observation. Respir. Med. 98(2), 134-138.
63. Gueli, N., Verrusio, W., Linguanti, A., De Santis, W., Canitano, N., Ippoliti, F., Marigliano, V., and Cacciafesta, M. (2010) Montelukast therapy and psychological distress in chronic obstructive pulmonary disease (COPD): a preliminary report. Arch. Gerontol. Geriatr. [Epub ahead of print]
64. Schmitt-Grohe, S. and Zielen, S. (2005) Leukotriene receptor antagonists in children with cystic fibrosis lung disease. Pediatr. Drugs 7, 353-363.
65. Schmitt-Grohe, S., Eickmeier, O., Schubert, R., Bez, C., and Zielen, S. (2002) Anti-inflammatory effects of montelukast in mild cystic fibrosis. Ann. Allergy Asthma Immunol. 89, 599-605.
66. Stelmach, I., Korzeniewska, A., Stelmach, W., Masjak, P., Grqelewski, T., and Jerzynska, J. (2005) Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Ann. Allergy Asthma Immunol. 95, 372-380.
67. Bisgaard, H.; Study Group on Montelukast and Respiratory Syncytial Virus (2003) A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. J. Respir. Crit. Care Med. 167, 379-383.
68. Han, J., Jia, Y., Takeda, K., Shiraishi, Y., Dakhama, A., and Gelfand, E.W. (2010) Montelukast during primary infection prevents airway hyperresponsiveness and inflammation following re-infection with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. [Epub ahead of print].
69. Fitzgerald, D.A. and Mellis, C.M. (2006) Leukotriene receptor antagonists in virus-induced wheezing: evidence to date. Treat. Respir. Med. 5, 407-417.
70. Tofociv, S.P., Zacharia, L.C., Carcillo, J.A., and Jackson, E.K. (2000) Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo. Clin. Exp. Pharmacol. Physiol. 27, 787-792.
71. Thomas, N.J., Carcillo, J.A., Herzer, W.A., Mi, Z., Tofociv, S.P., and Jackson, E.K. (2003) Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats. Eur. J. Pharmacol. 465, 133-139.
72. Coimbra, R., Melbostad, H., Loomis, W., Porcides, R.D., Wolf, P., Tobar, M., and Hoyt, D.B. (2006) LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-κB, and ICAM-1. J. Trauma 60, 115-125.
73. Ishizaka, A., Wu, Z.H., Stephens, K.E., Harada, H., Hogue, R.S., O'Hanley, P.T., and Raffin, T.A. (1988) Attenuation of acute lung injury in septic guinea pigs by pentoxifylline. Am. Rev. Respir. Dis. 138(2), 376-382.
74. Fischer, W., Schudt, C., and Wendel, A. (1993) Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice. Biochem. Pharmacol. 45(12), 2399-2404.
75. Lira, E.C., Graca, F.A., Goncalves, D.A., Zanon, N.M., Baviera, A.M., Strindberg, L., Lönnroth, P., Migliorini, R.H., Kettelhut, I.C., and Navegantes, L.C. (2007) Cyclic adenosine monophosphate-phosphodiesterase inhibitors reduce skeletal muscle protein catabolism in septic rats. Shock 27(6), 687-694.
76. Choi, W.I., Kwon, K.Y., Seo, J.W., Beagle, J., Quinn, D.A., and Hales, C.A. (2009) The role of phosphodiesterase 3 in endotoxin-induced acute kidney injury. BMC. Infect. Dis. 1, 9-80.
77. Wang, W., Zolty, E., Falk, S., Basava, V., Reznikov, L., and Schrier, R. (2006) Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am. J. Physiol. Renal Physiol. 291(5), F1090-F1095.
78. Carcillo, J.A., Herzer, W.A., Mi, Z., Thomas, N.J., and Jackson, E.K. (1996) Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine. J. Pharmacol. Exp. Ther. 279(3), 1197-1204.
79. Zhu, L., Pearce, D., and Kim, K.S. (2010) Prevention of E. coli K1 penetration of the blood-brain barrier by counteracting host cell receptor and signaling molecule involved in E. coli invasion of human brain microvascular endothelial cells. Infect. Immun. 78, 3554-3559.
80. Sener, G., Sehirli, O., Cetinel, S., Erca, F., Yuksel, M., Gedik, N., and Yegen, B.C. (2005) Amelioration of sepsis-induced hepatic and ileal injury in rats by the leukotriene receptor blocker montelukast. Prostaglandins Leukot. Essent. Fatty Acids 73, 453-462.